MaxCyte Unveils Operational Restructuring Aimed at Cost Reduction and Faster Profitability

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Sep 22 2025

0mins

MXCT+2.4%

Should l Buy MXCT?

Source: Newsfilter

Workforce Reduction Announcement: MaxCyte, Inc. is restructuring its operations, resulting in a 34% reduction of its global workforce to align resources with strategic priorities, aiming for annualized savings of approximately $13.6 million.
Financial Outlook: The company anticipates flat to a 10% decline in core revenue for 2025 compared to 2024, while expecting around $5 million in SPL program-related revenue and a year-end cash position of at least $155 million.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy MXCT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on MXCT

Wall Street analysts forecast MXCT stock price to rise

5 Analyst Rating

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.793

Low

4.94

Averages

6.92

High

8.89

Current: 0.793

Low

4.94

Averages

6.92

High

8.89

BTIG

Buy

Neutral

downgrade

2025-08-11

Reason

BTIG

Price Target

AI Analysis

2025-08-11

downgrade

Buy

Neutral

Reason

BTIG downgraded MaxCyte to Neutral from Buy without a price target after \"a tough Q2 business update\" and lowering of the bar for 2025. MaxCyte lowered its 2025 revenue guide by $5M, or 14% of its business, citing ongoing challenges for many of its cell and gene therapy customers to obtain capital to fund programs, purchase capital, or lease its systems, the analyst noted. The firm thinks the company still has a best-in-class electroporation platform, arguing that the \"number one driver to turn the business around is simply its customers becoming more readily able to raise money and invest in more programs.\"

William Blair

Matt Larew

Outperform -> Market Perform

downgrade

2025-08-07

Reason

William Blair

Matt Larew

Price Target

2025-08-07

downgrade

Outperform -> Market Perform

Reason

William Blair analyst Matt Larew downgraded MaxCyte to Market Perform from Outperform following the earnings report. The company reported a miss and guidance reduction in a strong bioprocessing tools tape, the analyst tells investors in a research note. The firm attributes the miss to MaxCyte's customer exposure and less visible revenue profile. William Blair believes the company's visibility seems lower than peers.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MXCT

Unlock Now

About MXCT

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Cellares Appoints New CCO to Support 2026 Clinical Trials

Dec 01 2025Newsfilter

Executive Appointment: Cellares has appointed Ali Soleymannezhad as Chief Commercial Officer, who brings over 20 years of commercialization experience in cell therapy and bioprocessing, aimed at driving the company's global commercial strategy in preparation for clinical trials in 2026.
Global Partnership Agreements: Cellares has signed multiple global manufacturing agreements with partners including Bristol Myers Squibb and Kite, establishing its leadership in cell therapy manufacturing and laying the groundwork for a future IPO.
Technological Innovation: Cellares' Cell ShuttleTM has received FDA's Advanced Manufacturing Technology designation, providing expedited review and regulatory support to lower manufacturing costs and accelerate global market entry for cell therapies.
Market Expansion: Cellares plans to establish a network of IDMO Smart Factories across the U.S., Europe, and Japan, which is expected to increase the batch output of each factory by tenfold, thereby meeting global patient demand for cell therapies.